Medindia

X

Vandetanib Study Enters Third Phase

by Ann Samuel on  February 27, 2007 at 2:35 PM Drug News   - G J E 4
Vandetanib Study Enters Third Phase
The Phase 3 study of the drug Vandetanib, marketed by London company AstraZeneca PLC has begun.

The study will cover 508 patients of lung cancer in whom the first-line treatment has failed. The study extends over 20 countries and 20 sites.
Advertisement

The patients who have a recorded a case of locally advanced or metastatic non-small cell lung cancer will be given the once-daily drug Vandetanib in addition to pemetrexed, as a second line treatment.

Advertisement
Says Medical Science Director for Vandetanib, Dr Peter Langmuir, 'After treatment failure with initial therapy, response rates to further treatment are low in patients with advanced non-small cell lung cancer.

'The effect of combining novel targeted agents, such as Vandetanib, with chemotherapy needs to be explored in order to further progress treatment options for patient benefit.'

The study will mainly focus on progression-free survival rates of the subjects.

Source: Medindia
ANN
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All